Literature DB >> 9330697

Further characterization of DPP IV-beta, a novel cell surface expressed protein with dipeptidyl peptidase activity.

J Blanco1, E Jacotot, C Callebaut, B Krust, A G Hovanessian.   

Abstract

By using a CD26 negative human lymphoblastoid cell line (C8166), here we describe the characterization of a cell-surface protein which manifests CD26-like dipeptidyl peptidase IV (DPP IV) activity. This protein, referred to as DPP IV-beta, shows a higher KM value for Gly-Pro-pNA than CD26 (0.31 mM compared to 0.11 mM, respectively). In addition, DPP IV-beta was found not to bind 125I-labeled adenosine deaminase (a property of human CD26). Gel filtration experiments using extracts from C8166 and MOLT4 (a CD26 positive human T cell line) cells, revealed that the apparent molecular mass of DPP IV-beta is 82 kDa, whereas that of CD26 is 110 kDa. In order to conveniently differentiate both activities, a new family of inhibitors, that selectively blocks peptidase activity associated to CD26, has been developed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330697     DOI: 10.1007/978-1-4757-9613-1_25

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.

Authors:  Shu Y Qi; Pierre J Riviere; Jerzy Trojnar; Jean-Louis Junien; Karen O Akinsanya
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis.

Authors:  Y N Williams; H Baba; S Hayashi; H Ikai; T Sugita; S Tanaka; N Miyasaka; T Kubota
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.